Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH…
Browsing: Acute Lymphoblastic Leukemia
Tim Stockwell, PhD of University of Victoria, British Columbia, Canada gives an overview of his presentation focused on alcohols contribution…
Stan Kaye, BSc, MD, FRCP, FRCR, FRSE, FMedSci of Royal Marsden NHS Foundation Trust, London, UK discusses drug resistance in…
Robert Coleman, MBBS, MD, FRCP, FRCPE of Sheffield Cancer Research, University of Sheffield, UK discusses issues with drug repurposing. Most…
Linda Bauld, PhD of the University of Stirling, UK discusses as session on the prevention of cancer at the population…
Elena Semino, PhD of Lancaster University, UK, discusses findings from research on how language can affect patients with cancer. There…
Cheng-Har Yip, MB, BS, FRCS of Breast Surgery International, Malaysia discusses the challenges in the management of breast cancer in…
Elaine Vickers, BMedSc, PhD of Science Communicated Ltd, Sheffield, UK gives an overview of sessions, which introduce an audience to…
Elena Semino, PhD, of Lancaster University, UK, provides an overview of a session on ‘How we talk about cancer’, which…
Keith McCrae, MD of Cleveland Clinic discusses the current treatment trends for non-malignant hematology at the 58th ASH Annual Meeting…
Keith McCrae, MD of Cleveland Clinic gives his view on pomalidomide in HHT care at the 58th ASH Annual Meeting…
Keith McCrae, MD of Cleveland Clinic discusses how patients with HHT disorder respond well to pomalidomide treatment at the 58th…
Jason Valent, MD of Cleveland Clinic discusses the 5 year outlook of plasma cell therapy in multiple myeloma at the…
Jason Valent, MD of Cleveland Clinic gives an overview of the current treatment trends for amyloidosis at the 58th ASH…
Jason Valent, MD of Cleveland Clinic talks about daratumumab in multiple myeloma at the 58th ASH Annual Meeting in San…
Jason Valent, MD of Cleveland Clinic discusses how new novel agents are changing the management of amyloidosis at the 58th…
Jason Valent, MD of Cleveland Clinic discusses how NEOD001 leads to clinical trials at the 58th ASH Annual Meeting in…
Jason Valent, MD of Cleveland Clinic discusses specific novel drugs that break down amyloid fibrils at the 58th ASH Annual…
David Miklos, MD, PhD of Stanford University Medical Center discusses the big news surrounding ibrutinib for Graft-versus-Host Disease at the…
David Miklos, MD, PhD of Stanford University Medical Center, discusses ibrutinib in Chronic Graft-versus-Host Disease at the 58th ASH Annual…
David Miklos, MD, PhD of Stanford University Medical Center, gives an overview of his abstract, Allogeneic Transplants from HLA-Mismatched Unrelated…
Jonathan Gerber, MD of Levine Cancer Institute discusses a novel approach from a translational research project in identifying stem cell…
Jonathan Gerber, MD of Levine Cancer Institute, discusses advances in research and treatment trends for AML at the 58th ASH…
Jonathan Gerber, MD of Levine Cancer Institute, gives an overview of a clinical study that shows pembrolizumab is active in…
Jonathan Gerber, MD of Levine Cancer Institute, talks about how targeting leukemia stem cell population may cure AML overall at…
Anne Neff, MD of Cleveland Clinic, gives an overview of the upcoming treatment trends for bleeding disorders in 2017 at…
Anne Neff, MD of Cleveland Clinic talks about how new research in hemophilia will impact clinical practitioners at the 58th…
Anne Neff, MD of Cleveland Clinic discusses how to prevent hemophilia from pain and functional impairment at the 58th ASH…
Anne Neff, MD of Cleveland Clinic, gives an overview of her abstract, Linear and Logistic Regression Models of Patient-Reported Outcomes…
Is there such thing as treatment-free remission for a CML patient? CML expert Dr. Jessica Altman of Robert H. Lurie…
What is the latest in myeloproliferative neoplasms (MPNs) from the American Society of Hematology (ASH) annual meeting and what does…
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses which ASH 2016 presentations were the…
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he reduced the number of…
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, talks about his Levine Cancer Institute program
Robert G. Uzzo, M.D. Willing G. Pepper Chairman of Surgery Fox Chase Cancer Center Temple University School of Medicine Chair,…
Paul Barr, MD gives his opinion on what will change in CLL treatment and therapy in the longterm at the…
Paul Barr, MD of University of Rochester gives an overview of the current trends and strategies in CLL treatment at…
Paul Barr, MD of University of Rochester, discusses data from the Resonate-2 Study at the 58th ASH Annual Meeting in…
Paul Barr, MD of University of Rochester, discusses how promising ibrutinib is as a first line treatment for older patients…
Paul Barr, MD of University of Rochester, discusses the use of ibrutinib in combination therapy from Resonate-2 Study at the…
Paul Barr, MD of University of Rochester, gives an overview of a clinical trial, Updated Efficacy and Safety from the…
David M. Foureau, PhD of Levine Cancer Institute gives an overview of the current trends for therapy in myeloma at…
MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center shares a comprehensive overview of the treatments for myeloproliferative neoplasms…
David M. Foureau, PhD of Levine Cancer Institute, talks about new and interesting data from myeloma study that was presented…
David M. Foureau, PhD of Levine Cancer Institute gives an overview of his abstract, Peripheral Immune Profile and Minimal Residual…
David M. Foureau, PhD of Levine Cancer Institute discusses targeted therapies for myeloma patients at the 58th ASH Annual Meeting…
David M. Foureau, PhD of Levine Cancer Institute discusses how targeting T-cells in myeloma may be the new focus for…
Parameswaran Hari, MD, MRCP, MS of Medical College of Wisconsin discusses the exciting new data in myeloma treatment that has…
Parameswaran Hari, MD, MRCP, MS of Medical College of Wisconsin gives his view on the outlook and future of treatments,…
Parameswaran Hari, MD, MRCP, MS of Medical College of Wisconsin talks about how the StaMINA trial will impact future clinical…